BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006 (Second Quarter of Fiscal Year 2006)
Business Overview: BD is a medical technology company operating through three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 6% year-over-year for the quarter and 8% for the six-month period. Growth was driven by volume increases of approximately 9%, partially offset by a 3% unfavorable impact from foreign currency translation.
• Profitability Decline: Net income decreased 18% for the quarter ($154.1M vs. $188.2M) and 3% for the six-month period ($371.9M vs. $383.5M). Diluted EPS from continuing operations dropped from $0.71 to $0.60 for the quarter.
• Acquisition Impact: The acquisition of GeneOhm Sciences, Inc. on February 14, 2006, resulted in a one-time charge of $53.3 million for acquired in-process research and development (IPR&D), recorded within R&D expenses. This charge reduced operating income and diluted EPS by approximately $0.21 for the quarter.
• Segment Performance:
  • Medical: Revenues up 9%; Operating income margin improved to 24.3% from 22.2%.
  • Diagnostics: Revenues up 1%; Operating income margin dropped significantly to 13.8% from 27.2% due to the $53M IPR&D charge.
  • Biosciences: Revenues up 8%; Operating income margin improved to 24.6% from 22.6%.
• Cost Pressures: The company faced higher resin purchase costs due to rising oil prices, though this was partially mitigated by productivity gains and sales mix shifts toward higher-margin products.

Guidance, Outlook, and Risks

• Outlook: Management expects gross profit margins to improve by 50 to 60 basis points in fiscal 2006. Selling and administrative expenses are expected to decrease by about 40 basis points as a percentage of revenue. R&D expenses are anticipated to increase approximately 33% for the full year, inclusive of the GeneOhm charge.
• Capital Allocation: The company repurchased approximately $225 million of common stock in the first six months. Capital expenditures for fiscal 2006 are expected to be in the $400 million range.
• Liquidity: The debt-to-capitalization ratio decreased to 25.7% from 27.3%. The company maintains a $900 million syndicated credit facility and a commercial paper program.
• Risks and Contingencies:
  • Foreign Exchange: Continued volatility in currency rates negatively impacts reported revenue and margins.
  • Raw Materials: Fluctuations in energy and resin costs could affect margins.
  • Regulatory/Competition: Risks include FDA approvals for competing products (e.g., inhaled insulin), patent expirations, and healthcare cost containment initiatives.
  • Legal: Ongoing litigation regarding product liability and environmental matters could result in material charges if outcomes are unfavorable.

Investor Verification Checklist

• GeneOhm Integration: Verify the strategic fit and future revenue contribution of the GeneOhm acquisition relative to the $53M immediate charge.
• Margin Sustainability: Assess whether the reported margin improvements can be sustained given rising raw material (resin) costs and foreign currency headwinds.
• Flu Season Variability: Review the impact of the mild 2006 flu season on Diagnostics revenue and the potential for volatility in future quarters.
• Share Repurchases: Confirm the remaining capacity under the authorized share repurchase programs ($10.7 million shares remaining).
• Pension Obligations: Monitor the $150 million discretionary pension contribution made in Q1 and its impact on future cash flows.